Form 4: Akero Therapeutics CEO Sells Shares to Cover Tax Obligations

Akero Therapeutics, Inc. President and CEO Andrew Cheng sold 6,620 shares of common stock for tax withholding purposes at a weighted-average price of $54.84 per share.

Summary

• Andrew Cheng, President and CEO, and a Director of Akero Therapeutics, Inc. (AKRO), reported a transaction on June 18, 2025.
• He sold 6,620 shares of Akero Therapeutics common stock.
• The shares were sold at a weighted-average price of $54.84 per share, with prices ranging from $54.73 to $54.84.
• This sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units.
• The transaction was automatic and not at the discretion of Mr. Cheng, following the Issuer's 'sell-to-cover' policy.
• Following this transaction, Mr. Cheng beneficially owns 549,867 shares of Akero Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary 'sell-to-cover' for tax purposes, which does not typically signal a change in management's confidence or company fundamentals.

Positives

• The sale was a non-discretionary 'sell-to-cover' transaction, meaning it was an automatic sale to satisfy tax withholding obligations upon the vesting of restricted stock units, rather than a discretionary sale by the insider.
• The company has a clear 'sell-to-cover' policy, which is a standard practice for managing executive equity compensation and associated tax liabilities.

Negatives

• The transaction resulted in a reduction of 6,620 shares from the direct beneficial ownership of a key executive, Andrew Cheng.

Future Outlook

NA

Management Comments

• The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

This is a routine insider transaction related to executive compensation and tax obligations, common across all industries, including biotechnology.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not indicative of a change in company outlook or management confidence.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Akero Therapeutics, AKRO, Andrew Cheng, SEC Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Sell-to-Cover, Biotechnology, Pharmaceuticals